Type I Interferon Counteracts Antiviral Effects of Statins in the Context of Gammaherpesvirus Infection.
J Virol
; 90(7): 3342-54, 2016 Jan 06.
Article
en En
| MEDLINE
| ID: mdl-26739055
ABSTRACT
UNLABELLED The cholesterol synthesis pathway is a ubiquitous cellular biosynthetic pathway that is attenuated therapeutically by statins. Importantly, type I interferon (IFN), a major antiviral mediator, also depresses the cholesterol synthesis pathway. Here we demonstrate that attenuation of cholesterol synthesis decreases gammaherpesvirus replication in primary macrophages in vitro and reactivation from peritoneal exudate cells in vivo. Specifically, the reduced availability of the intermediates required for protein prenylation was responsible for decreased gammaherpesvirus replication in statin-treated primary macrophages. We also demonstrate that statin treatment of a chronically infected host attenuates gammaherpesvirus latency in a route-of-infection-specific manner. Unexpectedly, we found that the antiviral effects of statins are counteracted by type I IFN. Our studies suggest that type I IFN signaling counteracts the antiviral nature of the subdued cholesterol synthesis pathway and offer a novel insight into the utility of statins as antiviral agents. IMPORTANCE Statins are cholesterol synthesis inhibitors that are therapeutically administered to 12.5% of the U.S. POPULATION Statins attenuate the replication of diverse viruses in culture; however, this attenuation is not always obvious in an intact animal model. Further, it is not clear whether statins alter parameters of highly prevalent chronic herpesvirus infections. We show that statin treatment attenuated gammaherpesvirus replication in primary immune cells and during chronic infection of an intact host. Further, we demonstrate that type I interferon signaling counteracts the antiviral effects of statins. Considering the fact that type I interferon decreases the activity of the cholesterol synthesis pathway, it is intriguing to speculate that gammaherpesviruses have evolved to usurp the type I interferon pathway to compensate for the decreased cholesterol synthesis activity.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Antivirales
/
Lovastatina
/
Interferón Tipo I
/
Colesterol
/
Gammaherpesvirinae
/
Infecciones por Herpesviridae
/
Inhibidores de Hidroximetilglutaril-CoA Reductasas
Límite:
Animals
Idioma:
En
Revista:
J Virol
Año:
2016
Tipo del documento:
Article
País de afiliación:
Estados Unidos